# Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

> **NCT01907854** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 407 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** sitagliptin
- **DRUG:** placebo
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01907854
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-02
- **Primary completion:** 2015-06-15
- **Final completion:** 2015-06-15
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907854, "Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01907854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*